Abstract
We aimed to measure social protection (SP) coverage among the general population and women and men living with HIV (WLHIV, MLHV), female and male sex workers (FSW, MSW), men who have sex with men (MSM), adolescent girls young women (AGYW), and orphans vulnerable children (OVC). We used Population-Based HIV Impact Assessments data from Eswatini, Malawi, Tanzania and Zambia. We generated survey-weighted proportions for each population group receiving any SP benefits, along with 95% confidence intervals (CI) using jackknife variance estimation. The proportion reported receiving SP benefits among the general population ranged from 7.7% (95% CI: 6.7%–8.8%) in Zambia to 39.6% (95% CI: 36.8%– 42.5%) in Eswatini. SP benefits by WLHIV, MLHIV, AGYW, OVC, SW and MSM – were lower than the 2017-19 global average of 45%. Data on access to SP benefits by people living with or affected by HIV from other regions is needed to estimate their SP coverage better.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge technical and financial support from the Joint United Nations Programme on AIDS (UNAIDS). Olivia Keiser was supported by the Swiss National Science Foundation (grant no 163878). We also thank the participants UNAIDS convened in Geneva 16 - 17, December 2019, to review and input into the conceptual framework for developing a methodology to estimate social protection coverage among people living with, at risk of and affected by HIV.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail addresses of co-authors: AP: apettif{at}email.unc.edu
JE: jkedwar{at}email.unc.edu
DG: dgiovenco{at}unc.edu
HMT: h.topazian{at}imperial.ac.uk
RMB: rb3221{at}cumc.columbia.edu
MCM mm5545{at}cumc.columbia.edu
JE: janne.estill{at}unige.ch
OK: Olivia.Keiser{at}unige.ch
JEJ: jj2158{at}cumc.columbia.edu
Data Availability
We obtained the PHIA data sets from the PHIA Project website at https://phia-data.icap.columbia.edu/files.